Category: Mid Day Movers

There is no fundamental reason why the IronNet, Inc. (IRNT) stock plummeted 18.29% in the current-market trading session at the price of $33.83. IRNT is a leading cybersecurity company. It delivers the first-ever Collective Defense sales operating platform to transform the way organizations secure their networks. It solves challenging cyber problems by integrating deep tradecraft knowledge into its industry-leading products.  

IRNT Fiscal Second Quarter 2022 Financial Results 

On 14th September 2021, IRNT published its financial and operating results for the second quarter ended 31st July 2021. CFO of IronNet, James Gerber, remarked that during their first half of fiscal 2022, the greater company deployments had shifted the expected closing of numerous new customer contracts into the third quarter. In the first half of the year, their cloud-based subscription revenue increased to 60% of product revenue. It represents a subsequential growth rate of 65% year-over-year. Their cloud focus reflects the company’s ease of deployment and increase market recognition. They are expecting to double ARR in the third quarter to meet their full-year growth objectives, he concluded.  

Fiscal Second Quarter 2022 Financial Highlights 

IRNT reported revenue of $6.1 million for the second quarter ended 31st July 2021. The total revenue was approximately $7.9 million in the same quarter of the previous year. Subscription revenue increased by $5.8 million in the second quarter of fiscal 2022 from $5.3 million in the same quarter last year.

Operating loss was $17.0 million for the second quarter ended 31st July 2021. For the same quarter of the previous year, the operating loss was $14.2 million. IRNT reported a net loss of $17.2 million for the fiscal 2022 second quarter. Net loss was $14.3 million in the same quarter last year. Cash and cash equivalents were $14.1 million for the fiscal 2022 second quarter.  

Philanthropic Partnership With 9/11 Memorial & Museum 

On 10th September 2021, IRNT announced the expansion of its philanthropic partnership with the 9/11 Memorial & Museum. The extended partnership will sponsor the 9/11 Memorial’s fifth annual Summit on Security in November 2021.  The company will assist in the 9/11 Memorial’s efforts by providing timely educational and public programming. The Summit will bring corporate and civic leaders on a national platform to discuss national security, counterterrorism, and combating attacks facing the United States. IRNT has also announced that 11th September will be a public service day for company employees. The working staff will have the opportunity to participate in charitable activities or volunteer through other service opportunities. 

Vascular Biogenics Ltd. (VBLT) stock declined 0.84% in the current-market trading session at the price of $2.37 following the clearance granted by DSMC to further continue the clinical research of its ongoing OVAL Phase 3 study of VB-111. VBLT is a clinical-stage biopharmaceutical company. It discovers, produces, and commercializes first-in-class therapies to treat cancer and inflammatory indications. 

DSMC Granted Clearance to Proceed OVAL Phase 3 Study of VB-111 

On 17th September 2021, VBLT published that DSMC has conducted its fifth pre-planned review of the OVAL Phase 3 study of VB-111 in patients with ovarian cancer. The independent Data Safety Monitoring Committee has also granted clearance to continue clinical research with no protocol changes. The DSMC had tasked with setting safety standards, monitoring standards’ implementation, and treatment efficacy data, and acting on behalf of patients where necessary. The OVAL trial has already been recruited more than 320 patients and is planning to enroll 400 more adult patients globally. The two primary endpoints of the trial are progression-free survival (PFS) and overall survival (OS). Successfully meeting the primary endpoint will support the biologics license application (BLA).  

CEO of VBLT, Prof. Dror Harats, remarked that they are happy to learn that data collected in the OVAL clinical trial had passed independent DSMC review. He thanked the DSMC for its continuous guidance and support in their clinical trial of VB-111 in ovarian cancer.   

VBLT to Present at Upcoming Conferences 

On 10th September 2021, VBLT announced that it would present at the upcoming industrial conference on 22nd September 2021. Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on Wednesday, from 1:15 PM to 1:55 PM (ET). Webcasts will be available on Company’s Investor Relations page at the “Events and Presentations” section.  

VBLT Resumed U.S. Enrollment in OVAL Phase 3 Trial   

On 30th August 2021, VBLT announced that it had resumed enrollment of new patients in VB-111 studies following authorization granted by the Food and Drug Administration. The VB-111 had produced in VBL’s commercial-scale GMP Modiin at Israel facility. The Chemistry, Manufacturing, and Controls Group of FDA permitted the company to use new batches of ofranergene obadenovec in clinical studies in the United States. Earlier in June, VBLT had been notified by FDA about the pending technical review of clearance of its new VB-111 batches for clinical use in the U.S. In early August, the company submitted the requested data and documentation to the CMC group of FDA to continue the review process.  

Kroger Co. (KR) stock prices were down by 7.05% some time after market trading commenced on September 10^th, 2021. This brought the price per share down to USD$42.88 early on in the trading day.

KR Stock’s Strategic Focus

KR stock’s strategic focus is on leading with fresh while accelerating with digital. This is hoped to continue to build momentum across the business. The seamless working of the company’s ecosystem was evidenced by the seamless shift of customers between channels. This resulted in a continuation of strong digital engagement. Trends indicate that customers are eating more food at home. This is driven by affordability, convenience, and health-consciousness, as compared to alternatives.

Mitigating Effects of Pandemic

The company’s associates have continued supporting their customers and communities through the challenges presented by the pandemic. This is facilitated by the delivery of a full, fresh, and friendly experience every day. KR stock is committed to its environmental, social, and governance strategy. It hopes that this will result in positive outcomes for both customers and the planet, with the creation of more resilient global systems. The company’s Zero Hunger | Zero Waste social and environmental impact plan drives the company’s aims.

Gross Margin Reports

Gross margin for the second quarter of fiscal 2021 came out to 21.4% of sales. The FIFO gross margin rate excluded fuel and was down 60 points as compared to the prior year quarter. the year over year decrease was largely driven by continued price investments. Further consolidating the yearly difference was higher shrink and supply chain costs. Sourcing benefits and growth in the alternative profit business partially offset the year over year decrease.

Additional KR Stock Financials

The LIFO charge for the second quarter of fiscal 2021 came out to USD$47 million. This is comparable to the USD$23 million reported in the prior year quarter. the year over year increase was largely driven by inflation in fresh categories. KR stock reported Operating, General, and Administrative rate was down by 76 points, excluding fuel and adjustment items. This reflects lower Covid-19 related costs, as well as the execution of cost savings initiatives.

Future Outlook for KR Stock

The company reported a promising quarter, as evidenced by its financial reports for Q2 2021. KR stock is poised to capitalize on the opportunities afforded to it as consumer trends continue during the persistent pandemic. Current and potential investors are hopeful that management will be able to usher in organic growth over the long term.

A-Mark Precious Metals Inc. (AMRK) stock prices surged by 14.30% some time after market trading commenced on September 10^th, 2021. This brought the price per share up to USD$59.48 early on in the trading day.

AMRK Stock’s Revenue Reports

Revenues for the fourth quarter of fiscal 2021 were reported at USD$2.18 billion. This represents a 31% increase from the USD$1.67 billion reported in the prior year quarter. As compared to the quarter ended March 31^st 2021, Q4 2021 reported revenues in the amount of USD$2.05 billion. The year over year and quarter over quarter increases were largely driven by an increase in sales. Specifically, the total amount of gold and silver ounces sold was up substantially. The increase was consolidated by the higher selling prices of gold and silver, while being partially offset by lower forward sales. Q4 2021 results included USD$603.8 million in revenue from AMRK stock’s acquisition of JMB.

Gross Profit Breakdown

Gross profits for the fourth quarter of fiscal 2021 came out to USD$87.1 million, the highest ever recorded for the company. This represented a 211% year over year increase from the USD$28 million reported for the quarter ended June 30^th 2020. As compared to the USD$68.2 million in revenue reported for the quarter ended March 31^st 2021, this is a 28% year over year increase. This year over year and quarter over quarter increase was largely attributable to higher gross profits earned by the Wholesale Sales and Ancillary Services and Direct-to-Consumer segments.

SG&A Costs

Selling, general, and administrative expenses were reported at USD$25 million for the fourth quarter of fiscal 2021. This is a 144% increase from the USD$10.2 million reported in the prior year quarter. this year over year increase was largely driven by USD$12.8 million in expenses incurred by the recently acquired JMB. USD$7.7 million of this total was attributable to amortization expense. Overall increases in consulting costs came out to USD$0.5 million, while compensation expense was reported at USD$0.3 million. Insurance costs were USD$0.7 million for the quarter. Overall, 51% of the total consolidated SG&A costs for the quarter were attributable to JMB.

Future Outlook for AMRK Stock

The company reported an encouraging quarter, as evidenced by the success of its financial reports for the Q4 2021. AMRK stock is poised to capitalize on the momentum generated over the course of fiscal 2021 into the start of fiscal 2022. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

Vince Holding Corp. (VNCE) stock prices surged by 16.39% as of the market closing on September 10^th, 2021. This brought the price per share up to USD$7.81 early on in the trading day.

Net Sales Reports

Total net sales for the second quarter of fiscal 2021 were reported in the amount of USD$78.7 million. This represents a 112.5% year-over-year increase from the USD$37 million reported for the prior-year quarter. Net loss for the 2021 quarter came out to USD$0.6 million, representing a net loss of USD$0.05 per share. This is comparable to the USD$15.1 million net loss reported in the prior-year quarter, which came out to a net loss of USD$1.28 per share.

Gross Profit and Margin

VNCE stock reported a gross profit in the amount of USD$35.4 million for the second quarter of fiscal 2021. This accounted for 45% of net sales for the quarter. The prior-year quarter saw the company report gross profit in the amount of USD$13.3 million, which came out to 36% of net sales. The year-over-year increase was largely attributable to channel mix, lower year-over-year adjustments to inventory reserves, and lower promotional activity in the direct-to-consumer channel.

VNCE Stock’s SG&A Costs

Selling, general, and administrative costs came out to USD$32.7 million for the second quarter of fiscal 2021. This represents 41.6% of sales for the quarter. These figures are comparable to the USD$27.3 million SG&A costs reported for Q2 2020, which represented 73.9% of net sales. The year-over-year increase was largely driven by higher payroll and compensation expenses, increased investments in marketing, and increase consulting and other third-party costs.

VNCE Stock’s Capital

The end of the second quarter of fiscal 2021 saw VNCE stock report total borrowings in the amount of USD$87.3 million. In addition to these debt agreements, the company also reported USD$34.4 million of surplus availability under its revolving credit facility. September 7^th, 2021 saw the company enter into a new USD$35 million senior secured term loan credit facility

Future Outlook for VNCE Stock

VNCE stock reported a promising quarter, as evidenced by the strength of its financial reports for Q2 2021. The company plans to continue allocating resources towards maintaining the momentum generated over H1 2021. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value over the long term.

Blade Air Mobility, Inc. (BLDE) stock rallied in intraday trading today after it announced the acquisition of Trinity Air Medical, Inc. BLDE stock price saw an uptrend of 13.76% to reach 10.00 a share at the time of this writing. The trading volume as of now was 1,131,869, significantly higher than the average volume.

Blade Air Mobility, Inc is the air alternative transporter to the congested ground routes in the U.S and across the globe. It was incorporated in 2014 and is headquartered in New York.

BLDE stock to acquire Trinity Air Medical, Inc:

Blade Air Mobility today signed the definitive agreement in order to acquire Trinity Air Medical, Inc.  The purchase price for 100% capital stock of trinity is $23 million. Moreover, additional consideration also includes in the transaction based on the EBITDA growth target in three years tenure.

Seth Bacon and Scott Wunsch will serve as the CEO and COO of Blade MediMobility respectively. Both of them have acknowledged a five-year non-competition agreement. All Trinity employees will get incentives and expect to remain to continue to work in the company after the transaction.

Trinity is the organ logistics and transportation company that generated $16 million in revenue in 2020. The company is currently operating in 16 states.

Financial View of BLDE stock:

BLDE stock generated $13.0 million in revenues in the fiscal third quarter ended June 30, 2021. This represents an extraordinary increase of 277% as compared to the prior-year period. The short distance revenue of Blade Air highly increased by 810% to reach $5.7 million compared to $0.6 million in the same prior-year period. The increase was due to the resumption of travel due to ease in covid restrictions. MediMobility organ transport and jet revenues reached $6.5 million, 147% higher than the same tenure of the previous year.

Blade Air reported a $24.3 million net loss in the third fiscal quarter of 2021. This compares to the net loss of $1.3 million in the same tenure of 2020. Stock-based compensation, change in fair value of warrant liabilities, and one-time BLDE stock’s public listing resulted in an increased net loss. Adjusted EBITDA was $2.6 million in the fiscal third quarter of 2021 as compared to $1.3 million in 2020.

Wrap Up:

The market sentiment of BLDE stock suggests that investors are happy with the recent development of Blade Air Mobility. As of now, the BLDE stock price has progressed 29.52% in the last 30 days.

Soligenix, Inc. (SNGX) stock was popping high today after it announced a grant of orphan drug designation by the FDA to treat T-cell Lymphoma. SNGX stock price saw a surge of 21.90% to reach $1.28 a share as of this writing. Soligenix stock was gloomy in the previous trade and went down by 3.67% at closing.

Soligenix, Inc is the late-stage biopharmaceutical stock that develops and commercializes for the treatment of rare diseases. The company is running its business mainly through two segments which are Specialized Biotherapeutics and Public Health Solutions. Let’s discuss recent events of this stock.

Orphan Drug Designation:

SNGX stock today announced that it has received a grant of orphan drug designation by the U.S Food & Drug Administration. The grant is related to the active ingredient hypericin to treat T-cell lymphoma. FDA extended target population of hypericin orphan drug designation beyond cutaneous T-cell lymphoma.

U.S Orphan Drug Act helps companies in developing safe and effective treatments against rare diseases and disorders. Now SNGX stock is in a position to leverage financial and regulatory benefits through orphan drug designation.  The management is now keen to advance the program toward NDA filing in the first half of 2022.

SNGX stock is preparing to tackle future health emergencies:

In July, Dr. Anthony Fausi urged to develop a prototype vaccine against different viruses for timely preparation for future health emergencies. At the University of Hawai’i in Mānoa SNGX stock’s collaborators are working with thermostabilized vaccine candidates against three life-threatening filoviruses which also include Sudan ebolavirus. Filoviruses may cause severe damage in areas with uncertain power supply. Developing thermostable vaccines can control rising concerns of the potential pandemic in such areas.

HyBryte: A therapy to treat rare diseases by SNGX stock:

In the last week of June, Dr. Ellen Kim, a lead principal investigator of SNGX stock discussed the efficacy and safety profile of HyBryte. According to Kim, HyBryte was safe and effective in most of the CTCL patients. A total of 169 patients participated in the flash study. The purpose of developing HyBryte is to provide a safe alternative to the existing therapies that cause significant and fatal side effects.

Conclusion:

The orphan drug designation by the FDA has made the SNGX stock green in the stock market. By the end of June 2021, SNGX stock had $29 million in cash position which reflects sufficient capital to pursue its strategic goals.